Tarsa Therapeutics has entered into a commercial supply agreement with QS Pharma for the bulk manufacture of its OSTORA oral recombinant salmon calcitonin tablet. QS Pharma will manufacture the tablets at its facility in PA and they will be used for product launch and commercial sale. QS Pharma had initially supplied small-scale development batches; scale-up and validation activities are currently underway.   Tarsa is preparing to file a NDA with the FDA for OSTORA tablet for the treatment of po...